Abstract
Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
Original language | English |
---|---|
Pages (from-to) | 7-11 |
Number of pages | 5 |
Journal | Biologics: Targets & Therapy |
Volume | 7 |
DOIs | |
Publication status | Published - 9 Jan 2013 |
Keywords
- IL-5
- asthma
- eosinophil